AU2025242246A1 — Novel pharmaceutical composition
Assigned to Novartis AG · Expires 2025-10-23 · 1y expired
What this patent protects
The invention pertains to dispersible tablets comprising as active ingredient N-{3-[5-(2-Amino-4 pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2- fluorophenyl}-2,6-ifluorobenzenesulfonamide, methanesulfonate salt, hypromellose, and at least one pharmaceutically acceptable …
USPTO Abstract
The invention pertains to dispersible tablets comprising as active ingredient N-{3-[5-(2-Amino-4 pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2- fluorophenyl}-2,6-ifluorobenzenesulfonamide, methanesulfonate salt, hypromellose, and at least one pharmaceutically acceptable excipient suitable for the preparation of tablets, wherein the Compound A is present in an amount of from 5% to 40% in weight based on the total weight of the tablet, processes for preparing the same, and processes for using the same, preferably for the treatment of cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.